Bridgewater Associates’s AngioDynamics ANGO Stock Holding History

Bridgewater Associates’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-41,002	Closed	-$428K	–	743
2023 Q2	$428K	Sell	41,002 -5,714	-12%	-$55K	﹤0.01%	657
2023 Q1	$483K	Buy	46,716 +1,791	+4%	+$22.9K	﹤0.01%	652
2022 Q4	$619K	Sell	44,925 -15,190	-25%	-$211K	﹤0.01%	701
2022 Q3	$1.23M	Buy	60,115 +296	+0.5%	+$6.5K	0.01%	661
2022 Q2	$1.16M	Buy	59,819 +5,467	+10%	+$112K	﹤0.01%	779
2022 Q1	$1.17M	Buy	54,352 +12,603	+30%	+$286K	﹤0.01%	780
2021 Q4	$1.15M	Buy	41,749 +1,793	+4%	+$49.5K	0.01%	545
2021 Q3	$1.04M	Sell	39,956 -165	-0.4%	-$4.41K	0.01%	514
2021 Q2	$1.09M	Buy	+40,121	New	+$980K	0.01%	569

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgewater Associates's ANGO Position: Q3 2023 in Review

Bridgewater Associates sold out of AngioDynamics (ANGO) in Q3 2023, closing a stake of 41,002 shares — an estimated $428K sold.

Bridgewater Associates first reported a position in ANGO in Q2 2021 and held it in 9 quarters. The position peaked at $1.23M in Q3 2022. 154 funds tracked by Wall St. Rank hold ANGO as of Q3 2023.

Bridgewater Associates reported no remaining AngioDynamics position as of Q3 2023 after selling out during the quarter.
Bridgewater Associates sold 41,002 AngioDynamics shares in Q3 2023, an estimated $428K.
Bridgewater Associates first reported a position in AngioDynamics in Q2 2021 and held it in 9 quarters.
Bridgewater Associates's AngioDynamics position peaked at $1.23M in Q3 2022.
154 funds tracked by Wall St. Rank held AngioDynamics as of Q3 2023.

Based on Bridgewater Associates's 13F filing for Q3 2023, filed 13 Nov 2023.